(Reuters) - Boston Scientific Corp BSX.N swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID-19 pandemic.
The Marlborough, Massachusetts-based company said on Wednesday its sales of medical devices dropped 3.7% to $2.58 billion.
Earlier this year, the company withdrew its 2020 profit forecast, citing uncertainties due to the COVID-19 pandemic.
Rival Abbott Laboratories ABT.N, however, raised its 2020 profit forecast last week on strong COVID-19 testing revenue and a recovery in its medical device business.
Excluding items, Boston Scientific earned 37 cents per share in the third quarter.
Net sales fell 1.8% to $2.66 billion.
Net loss attributable to Boston Scientific was $169 million, or 12 cents per share, in the quarter ended Sept 30, compared with net earnings of $126 million, or 9 cents per share, last year.
Reporting by Trisha Roy and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.